Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Upstream Bio, Inc. (UPB)
USD7.27
+0.13 (+1.82%)
US NASDAQ Healthcare Biotechnology
Address
890 Winter Street 2451
Waltham, MA, US
Waltham, MA, US
CEO
E. Rand Sutherland
Website
upstreambio.com
IPO
2024-10-11
CIK 2022626 ISIN US91678A1079
Description
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD7.27
+0.13 (+1.82%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
607.7K
Beta
1.24
Float Shares
20.08M
Free Float %
36.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.39% | -8.13% | -32.89% | -33.91% | -77.57% | -77.53% | -45.39% | -72.27% | -72.27% | -72.27% | -72.27% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (3 ratings, all time)
Hold
Price Targets & DCF
Current price
7.27
Low
15.00
+106.3%
Consensus
33.00
+353.9%
Median
33.00
+353.9%
High
51.00
+601.5%
Ratings Trend (MoM)
89% Bullish
| Rating | 2026-06 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 6 | +1 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
15.00
+106.3%
|
| Last Year | 3 |
37.67
+418.2%
|
| All Time | 4 |
47.00
+546.5%
|
Quality scores
Altman Z-Score
12.04
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+20.4% ★ Q1'26: +82.7% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-78.5% Q1'26: -47.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-5,004.6% Q1'26: -4,627.9% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-5,026.0% Q1'26: -3,925.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: -1,541.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+4.9% Q1'26: +1.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q1'26: -0.01× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 8 EPS Ana. |
Dec 2027 5 Rev. Ana. 7 EPS Ana. |
Dec 2028 7 Rev. Ana. 7 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
Dec 2030 6 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
2.37M
est: 2.15M (+10.1%)
|
2.85M
est: 2.66M (+7.1%)
|
2.03M
1.61M – 2.27M
-23.7% YoY
|
1.93M
1.02M – 2.83M
-5.3% YoY
|
4.69M
3.19M – 5.96M
+143.7% YoY
|
10.09M
6.85M – 12.81M
+115.1% YoY
|
73.98M
50.24M – 93.91M
+632.9% YoY
|
| EBITDA |
-62.72M
est: -2.15M (-2,813.6%)
|
-143.26M
est: -2.66M (-5,276.3%)
|
-2.03M
-2.27M – -1.61M
+23.7% YoY
|
-1.93M
-2.83M – -1.02M
+5.3% YoY
|
-4.69M
-5.96M – -3.19M
-143.7% YoY
|
-10.09M
-12.81M – -6.85M
-115.1% YoY
|
-73.98M
-93.91M – -50.24M
-632.9% YoY
|
| EBIT |
-62.81M
est: -2.15M (-2,817.8%)
|
-143.44M
est: -2.66M (-5,283.3%)
|
-2.03M
-2.27M – -1.61M
+23.7% YoY
|
-1.93M
-2.83M – -1.02M
+5.3% YoY
|
-4.69M
-5.96M – -3.19M
-143.7% YoY
|
-10.09M
-12.81M – -6.85M
-115.1% YoY
|
-73.98M
-93.91M – -50.24M
-632.9% YoY
|
| Net Income |
-62.81M
est: -409.66M (+84.7%)
|
-143.44M
est: -142.17M (-0.9%)
|
-154.94M
-170.09M – -139.80M
-9.0% YoY
|
-154.24M
-190.36M – -118.12M
+0.5% YoY
|
-158.30M
-243.34M – -73.25M
-2.6% YoY
|
-181.04M
-244.46M – -105.51M
-14.4% YoY
|
-154.88M
-209.14M – -90.26M
+14.4% YoY
|
| SGA |
17.17M
est: 14.17M (+21.2%)
|
26.41M
est: 17.54M (+50.6%)
|
13.39M
10.60M – 14.97M
-23.7% YoY
|
12.67M
6.70M – 18.64M
-5.3% YoY
|
30.88M
20.97M – 39.20M
+143.7% YoY
|
66.43M
45.11M – 84.33M
+115.1% YoY
|
486.84M
330.60M – 618.05M
+632.9% YoY
|
| EPS |
-1.49
est: -8.03 (+81.4%)
|
-2.66
est: -2.60 (-2.5%)
|
-2.80
-3.16 – -2.60
-8.0% YoY
|
-2.86
-3.53 – -2.19
-1.9% YoY
|
-3.09
-4.52 – -1.36
-8.3% YoY
|
-3.36
-4.54 – -1.96
-8.7% YoY
|
-2.88
-3.88 – -1.68
+14.4% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-14 | Mizuho | Outperform | Outperform | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-09 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-06-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-06-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-06-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-06-03 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-06-02 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-06-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-139.48M
OE per share TTM
-2.58
Owner's Yield
-38.37%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
51.2%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
16
Total invested
16.65M
Insider transactions (90d)
0
Beneficial owners (>5%)
16
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | FMR LLC | 7.94M | 14.80% | — | — | — | — | HC | DELAWARE | 2025-08-06 | ↗ |
| 2 | Abigail P. Johnson | 6.07M | 11.82% | — | — | 6.07M | — | IN | Delaware | 2024-11-07 | ↗ |
| 3 | AI Biotechnology LLC | 5.49M | 10.70% | — | 5.49M | — | 5.49M | OO | — | 2024-10-22 | ↗ |
| 4 | AI Upstream LLC | 5.49M | 10.70% | 5.49M | — | 5.49M | — | OO | — | 2024-10-22 | ↗ |
| 5 | Access Industries Holdings LLC | 5.49M | 10.70% | — | 5.49M | — | 5.49M | OO | — | 2024-10-22 | ↗ |
| 6 | Access Industries Management, LLC | 5.49M | 10.70% | — | 5.49M | — | 5.49M | OO | — | 2024-10-22 | ↗ |
| 7 | Len Blavatnik | 5.49M | 10.70% | — | 5.49M | — | 5.49M | IN | — | 2024-10-22 | ↗ |
| 8 | OrbiMed Advisors LLC | 4.55M | 8.90% | — | 4.55M | — | 10.00 | IA | Delaware | 2024-10-17 | ↗ |
| 9 | OrbiMed Capital GP VIII LLC | 4.55M | 8.90% | — | 4.55M | — | 10.00 | OO | Delaware | 2024-10-17 | ↗ |
| 10 | Norges Bank | 2.88M | 5.30% | — | — | — | — | FI, OO | NORWAY | 2025-10-24 | ↗ |
| 11 | Decheng Capital Global Life Sciences Fund IV, L.P. | 2.72M | 5.00% | 2.72M | 2.72M | 2.72M | — | PN | CAYMAN ISLANDS | 2026-05-15 | ↗ |
| 12 | BCLS Fund III Investments, LP | 2.30M | 4.30% | — | 2.30M | — | 2.30M | PN | Delaware | 2024-10-18 | ↗ |
| 13 | HBM Healthcare Investments (Cayman) Ltd. | 2.20M | 4.10% | — | — | — | — | CO | CAYMAN ISLANDS | 2025-11-14 | ↗ |
| 14 | TCG Crossover GP I, LLC | 2.12M | 3.90% | 2.12M | 2.12M | 2.12M | — | OO | DELAWARE | 2025-11-14 | ↗ |
| 15 | OrbiMed Advisors Israel II Limited | 1.14M | 2.20% | — | 1.14M | — | 10.00 | CO | Cayman Islands | 2024-10-17 | ↗ |
| 16 | OrbiMed Israel GP II, L.P. | 1.14M | 2.20% | — | 1.14M | — | 10.00 | PN | Cayman Islands | 2024-10-17 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
16
-120 vs prev Q
New positions
4
Closed positions
121
Increased
9
Reduced
4
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | FMR LLC | 7.52M -568.2K (-7.0%) | 204.12M +52.0M (+34.2%) | 13.94% -1.098 pp | 0.01% +0.003 pp | USD15.92 +70.5% | 5 qtrs — |
| 2 | ORBIMED ADVISORS LLC | 5.69M +— (+0.0%) | 154.58M +47.5M (+44.3%) | 10.56% -0.031 pp | 3.17% +0.644 pp | USD16.44 +65.1% | 5 qtrs — |
| 3 | BLACKROCK, INC. | 3.34M +740.8K (+28.5%) | 90.80M +41.8M (+85.4%) | 6.20% +1.359 pp | 0.00% +0.001 pp | USD17.48 +55.3% | 5 qtrs — |
| 4 | DECHENG CAPITAL LLC | 3.14M -142.2K (-4.3%) | 85.33M +23.5M (+38.1%) | 5.83% -0.282 pp | 11.48% +0.698 pp | USD16.44 +65.1% | 5 qtrs — |
| 5 | NORGES BANK | 2.88M +2.9M (+100.0%) | 78.26M +78.3M (+100.0%) | 5.35% +5.345 pp | 0.01% +0.008 pp | USD27.15 +0.0% | 1 qtrs NEW |
| 6 | ENAVATE SCIENCES GP, LLC | 2.46M +— (+0.0%) | 66.78M +20.5M (+44.3%) | 4.56% -0.014 pp | 13.18% -0.949 pp | USD16.44 +65.1% | 5 qtrs — |
| 7 | VANGUARD GROUP INC | 2.39M -54.1K (-2.2%) | 64.85M +18.9M (+41.1%) | 4.43% -0.114 pp | 0.00% +0.000 pp | USD13.88 +95.6% | 5 qtrs — |
| 8 | UBS GROUP AG | 1.81M +1.5M (+563.4%) | 49.04M +43.9M (+857.5%) | 3.35% +2.843 pp | 0.01% +0.007 pp | USD25.28 +7.4% | 5 qtrs — |
| 9 | JANUS HENDERSON GROUP PLC | 1.53M +1.5M (+100.0%) | 41.42M +41.4M (+100.0%) | 2.83% +2.833 pp | 0.02% +0.019 pp | USD27.15 +0.0% | 1 qtrs NEW |
| 10 | ALTSHULER SHAHAM LTD | 1.34M -75.3K (-5.3%) | 36.42M +9.8M (+36.7%) | 2.49% -0.147 pp | 0.55% +0.113 pp | USD6.35 +327.6% | 4 qtrs — |
| 11 | BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 1.33M -1.1M (-45.5%) | 36.10M -9.8M (-21.3%) | 2.47% -2.072 pp | 2.76% -0.281 pp | USD16.12 +68.4% | 5 qtrs — |
| 12 | OMEGA FUND MANAGEMENT, LLC | 1.33M -30.0K (-2.2%) | 36.01M +10.5M (+41.1%) | 2.46% -0.063 pp | 12.57% +1.095 pp | USD16.44 +65.1% | 5 qtrs — |
| 13 | STATE STREET CORP | 1.32M +204.6K (+18.4%) | 35.82M +14.9M (+70.8%) | 2.45% +0.373 pp | 0.00% +0.001 pp | USD18.09 +50.1% | 5 qtrs — |
| 14 | VR ADVISER, LLC | 1.17M +— (+0.0%) | 31.75M +9.8M (+44.3%) | 2.17% -0.007 pp | 1.57% +0.330 pp | USD16.44 +65.1% | 5 qtrs — |
| 15 | WELLINGTON MANAGEMENT GROUP LLP | 894.7K -230.7K (-20.5%) | 24.29M +3.1M (+14.8%) | 1.66% -0.434 pp | 0.00% +0.001 pp | USD16.44 +65.1% | 5 qtrs — |
| 16 | GEODE CAPITAL MANAGEMENT, LLC | 851.9K +34.8K (+4.3%) | 23.13M +7.8M (+50.5%) | 1.58% +0.060 pp | 0.00% +0.000 pp | USD15.27 +77.8% | 5 qtrs — |
| 17 | PARKMAN HEALTHCARE PARTNERS LLC | 834.6K -8.9K (-1.1%) | 22.66M +6.8M (+42.8%) | 1.55% -0.021 pp | 2.16% +0.502 pp | USD10.82 +150.9% | 4 qtrs — |
| 18 | PICTET ASSET MANAGEMENT HOLDING SA | 773.1K +773.1K (+100.0%) | 20.99M +21.0M (+100.0%) | 1.43% +1.434 pp | 0.02% +0.020 pp | USD27.15 +0.0% | 1 qtrs NEW |
| 19 | WOODLINE PARTNERS LP | 760.3K +158.0K (+26.2%) | 20.64M +9.3M (+82.2%) | 1.41% +0.290 pp | 0.08% +0.027 pp | USD18.38 +47.7% | 5 qtrs — |
| 20 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 750.0K +175.0K (+30.4%) | 20.36M +9.5M (+88.3%) | 1.39% +0.321 pp | 1.01% +0.279 pp | USD20.76 +30.8% | 2 qtrs — |
| 21 | TCG CROSSOVER MANAGEMENT, LLC | 743.9K -1.4M (-64.9%) | 20.20M -19.6M (-49.3%) | 1.38% -2.558 pp | 0.67% -1.291 pp | USD16.44 +65.1% | 5 qtrs — |
| 22 | SAMSARA BIOCAPITAL, LLC | 736.0K -226.1K (-23.5%) | 19.98M +1.9M (+10.4%) | 1.36% -0.425 pp | 2.06% -0.301 pp | USD16.44 +65.1% | 5 qtrs — |
| 23 | VESTAL POINT CAPITAL, LP | 720.0K +720.0K (+100.0%) | 19.55M +19.5M (+100.0%) | 1.34% +1.335 pp | 0.66% +0.665 pp | USD27.15 +0.0% | 1 qtrs NEW |
| 24 | SIREN, L.L.C. | 588.5K -200.0K (-25.4%) | 15.98M +1.1M (+7.7%) | 1.09% -0.375 pp | 0.48% -0.104 pp | USD16.44 +65.1% | 5 qtrs — |
| 25 | BARCLAYS PLC | 524.5K +439.2K (+514.8%) | 14.24M +12.6M (+787.4%) | 0.97% +0.814 pp | 0.00% +0.003 pp | USD24.75 +9.7% | 5 qtrs — |
| 26 | MILLENNIUM MANAGEMENT LLC | 517.3K +477.2K (+1,189.5%) | 14.04M +13.3M (+1,761.3%) | 0.96% +0.885 pp | 0.01% +0.006 pp | USD26.50 +2.5% | 4 qtrs — |
| 27 | NANTAHALA CAPITAL MANAGEMENT, LLC | 495.0K -100.0K (-16.8%) | 13.44M +2.2M (+20.1%) | 0.92% -0.189 pp | 0.44% +0.056 pp | USD16.44 +65.1% | 5 qtrs — |
| 28 | MARSHALL WACE, LLP | 343.8K -524.2K (-60.4%) | 9.33M -7.0M (-42.8%) | 0.64% -0.977 pp | 0.01% -0.008 pp | USD17.86 +52.0% | 5 qtrs — |
| 29 | GOLDMAN SACHS GROUP INC | 333.5K +110.3K (+49.4%) | 9.05M +4.9M (+115.6%) | 0.62% +0.203 pp | 0.00% +0.001 pp | USD21.57 +25.9% | 5 qtrs — |
| 30 | GREAT POINT PARTNERS LLC | 300.0K +— (+0.0%) | 8.15M +2.5M (+44.3%) | 0.56% -0.002 pp | 2.64% +0.314 pp | USD16.44 +65.1% | 5 qtrs — |
| 31 | ALYESKA INVESTMENT GROUP, L.P. | 298.3K +298.3K (+100.0%) | 8.10M +8.1M (+100.0%) | 0.55% +0.553 pp | 0.02% +0.023 pp | USD27.15 +0.0% | 5 qtrs — |
| 32 | JENNISON ASSOCIATES LLC | 288.8K +288.8K (+100.0%) | 7.84M +7.8M (+100.0%) | 0.54% +0.536 pp | 0.00% +0.005 pp | USD27.15 +0.0% | 1 qtrs NEW |
| 33 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 284.9K +103.0 (+0.0%) | 7.74M +2.4M (+44.4%) | 0.53% -0.001 pp | 0.00% +0.000 pp | USD16.45 +65.0% | 5 qtrs — |
| 34 | NORTHERN TRUST CORP | 236.8K -17.9K (-7.0%) | 6.43M +1.6M (+34.2%) | 0.44% -0.035 pp | 0.00% +0.000 pp | USD14.71 +84.6% | 5 qtrs — |
| 35 | — | 230.7K +230.7K (+100.0%) | 6.26M +6.3M (+100.0%) | 0.43% +0.428 pp | 2.65% +2.654 pp | USD27.15 +0.0% | 1 qtrs NEW |
| 36 | INVESCO LTD. | 163.2K +146.0K (+849.3%) | 4.43M +4.1M (+1,270.2%) | 0.30% +0.271 pp | 0.00% +0.001 pp | USD26.00 +4.4% | 5 qtrs — |
| 37 | BOXER CAPITAL MANAGEMENT, LLC | 150.0K +150.0K (+100.0%) | 4.07M +4.1M (+100.0%) | 0.28% +0.278 pp | 0.89% +0.891 pp | USD27.15 +0.0% | 1 qtrs NEW |
| 38 | DEUTSCHE BANK AG\ | 127.8K +101.1K (+378.0%) | 3.47M +3.0M (+590.0%) | 0.24% +0.187 pp | 0.00% +0.001 pp | USD24.59 +10.4% | 5 qtrs — |
| 39 | MORGAN STANLEY | 122.1K +34.5K (+39.5%) | 3.31M +1.7M (+101.3%) | 0.23% +0.064 pp | 0.00% +0.000 pp | USD16.97 +60.0% | 5 qtrs — |
| 40 | SUMMITTX CAPITAL, L.P. | 116.7K +4.3K (+3.8%) | 3.17M +1.1M (+49.9%) | 0.22% +0.007 pp | 0.10% +0.008 pp | USD19.12 +42.0% | 2 qtrs — |
| 41 | SCHONFELD STRATEGIC ADVISORS LLC | 115.8K -74.4K (-39.1%) | 3.14M -434.3K (-12.1%) | 0.21% -0.139 pp | 0.01% -0.006 pp | USD8.62 +215.0% | 4 qtrs — |
| 42 | JPMORGAN CHASE & CO | 110.3K +80.3K (+268.3%) | 2.99M +2.4M (+431.5%) | 0.20% +0.149 pp | 0.00% +0.000 pp | USD24.47 +11.0% | 5 qtrs — |
| 43 | AMERICAN CENTURY COMPANIES INC | 87.8K +16.2K (+22.7%) | 2.38M +1.0M (+77.1%) | 0.16% +0.030 pp | 0.00% +0.001 pp | USD18.36 +47.9% | 3 qtrs — |
| 44 | BANK OF AMERICA CORP /DE/ | 86.4K +30.9K (+55.7%) | 2.35M +1.3M (+124.8%) | 0.16% +0.057 pp | 0.00% +0.000 pp | USD20.83 +30.3% | 5 qtrs — |
| 45 | BANK OF NEW YORK MELLON CORP | 84.9K -6.7K (-7.3%) | 2.30M +582.3K (+33.8%) | 0.16% -0.013 pp | 0.00% +0.000 pp | USD14.19 +91.3% | 5 qtrs — |
| 46 | NUVEEN, LLC | 78.6K +8.7K (+12.4%) | 2.13M +818.6K (+62.3%) | 0.15% +0.016 pp | 0.00% +0.000 pp | USD11.45 +137.1% | 4 qtrs — |
| 47 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 75.4K +75.4K (+100.0%) | 2.05M +2.0M (+100.0%) | 0.14% +0.140 pp | 0.02% +0.016 pp | USD27.15 +0.0% | 1 qtrs NEW |
| 48 | ARTIA GLOBAL PARTNERS LP | 68.7K +68.7K (+100.0%) | 1.86M +1.9M (+100.0%) | 0.13% +0.127 pp | 0.30% +0.297 pp | USD27.15 +0.0% | 1 qtrs NEW |
| 49 | EXOME ASSET MANAGEMENT LLC | 64.8K +12.9K (+24.8%) | 1.76M +783.2K (+80.1%) | 0.12% +0.024 pp | 0.84% +0.250 pp | USD20.47 +32.6% | 2 qtrs — |
| 50 | AMERIPRISE FINANCIAL INC | 56.6K +56.6K (+100.0%) | 1.54M +1.5M (+100.0%) | 0.10% +0.105 pp | 0.00% +0.000 pp | USD27.15 +0.0% | 1 qtrs NEW |
| 51 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 55.8K +55.8K (+100.0%) | 1.52M +1.5M (+100.0%) | 0.10% +0.104 pp | 0.00% +0.000 pp | USD27.15 +0.0% | 4 qtrs — |
| 52 | SEVEN GRAND MANAGERS, LLC | 50.0K +50.0K (+100.0%) | 1.36M +1.4M (+100.0%) | 0.09% +0.093 pp | 0.10% +0.103 pp | USD27.15 +0.0% | 1 qtrs NEW |
| 53 | Y-INTERCEPT (HONG KONG) LTD | 46.6K +46.6K (+100.0%) | 1.26M +1.3M (+100.0%) | 0.09% +0.086 pp | 0.03% +0.028 pp | USD27.15 +0.0% | 1 qtrs NEW |
| 54 | ALPS ADVISORS INC | 44.4K +18.4K (+70.9%) | 1.20M +716.5K (+146.7%) | 0.08% +0.034 pp | 0.01% +0.004 pp | USD20.88 +30.0% | 5 qtrs — |
| 55 | RHUMBLINE ADVISERS | 41.5K -7.9K (-16.0%) | 1.13M +198.0K (+21.3%) | 0.08% -0.015 pp | 0.00% +0.000 pp | USD12.67 +114.3% | 5 qtrs — |
| 56 | RAFFERTY ASSET MANAGEMENT, LLC | 38.7K +4.2K (+12.1%) | 1.05M +400.9K (+61.7%) | 0.07% +0.008 pp | 0.00% +0.002 pp | USD19.71 +37.7% | 2 qtrs — |
| 57 | WELLS FARGO & COMPANY/MN | 36.8K +11.6K (+46.2%) | 999.0K +525.7K (+111.1%) | 0.07% +0.021 pp | 0.00% +0.000 pp | USD18.00 +50.8% | 5 qtrs — |
| 58 | TREXQUANT INVESTMENT LP | 31.0K +31.0K (+100.0%) | 843.0K +843.0K (+100.0%) | 0.06% +0.058 pp | 0.01% +0.008 pp | USD27.15 +0.0% | 1 qtrs NEW |
| 59 | ALLIANCEBERNSTEIN L.P. | 31.0K +11.2K (+56.2%) | 841.9K +468.5K (+125.5%) | 0.06% +0.021 pp | 0.00% +0.000 pp | USD20.29 +33.8% | 5 qtrs — |
| 60 | AQR CAPITAL MANAGEMENT LLC | 30.5K +549.0 (+1.8%) | 828.2K +264.7K (+47.0%) | 0.06% +0.001 pp | 0.00% +0.000 pp | USD8.32 +226.3% | 4 qtrs — |
| 61 | D. E. SHAW & CO., INC. | 27.1K +27.1K (+100.0%) | 735.5K +735.5K (+100.0%) | 0.05% +0.050 pp | 0.00% +0.000 pp | USD27.15 +0.0% | 1 qtrs NEW |
| 62 | SWISS NATIONAL BANK | 26.6K +26.6K (+100.0%) | 722.2K +722.2K (+100.0%) | 0.05% +0.049 pp | 0.00% +0.000 pp | USD27.15 +0.0% | 1 qtrs NEW |
| 63 | DIADEMA PARTNERS LP | 20.5K +20.5K (+100.0%) | 556.6K +556.6K (+100.0%) | 0.04% +0.038 pp | 0.10% +0.096 pp | USD27.15 +0.0% | 1 qtrs NEW |
| 64 | METLIFE INVESTMENT MANAGEMENT, LLC | 19.7K -2.0K (-9.3%) | 534.3K +126.3K (+30.9%) | 0.04% -0.004 pp | 0.00% +0.001 pp | USD13.76 +97.3% | 5 qtrs — |
| 65 | PRICE T ROWE ASSOCIATES INC /MD/ | 19.6K +1.1K (+6.1%) | 534.0K +185.0K (+53.0%) | 0.04% +0.002 pp | 0.00% +0.000 pp | USD12.33 +120.2% | 3 qtrs — |
| 66 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 17.5K +628.0 (+3.7%) | 475.3K +160.7K (+51.1%) | 0.03% +0.001 pp | 0.00% +0.000 pp | USD14.16 +91.7% | 5 qtrs — |
| 67 | PRELUDE CAPITAL MANAGEMENT, LLC | 16.6K +825.0 (+5.2%) | 449.6K +153.6K (+51.9%) | 0.03% +0.001 pp | 0.03% +0.010 pp | USD19.23 +41.2% | 2 qtrs — |
| 68 | RENAISSANCE TECHNOLOGIES LLC | 16.4K +16.4K (+100.0%) | 445.3K +445.3K (+100.0%) | 0.03% +0.030 pp | 0.00% +0.001 pp | USD27.15 +0.0% | 1 qtrs NEW |
| 69 | QUANTINNO CAPITAL MANAGEMENT LP | 15.4K +526.0 (+3.5%) | 418.5K +138.5K (+49.4%) | 0.03% +0.001 pp | 0.00% +0.000 pp | USD10.36 +162.1% | 4 qtrs — |
| 70 | XTX TOPCO LTD | 15.1K +15.1K (+100.0%) | 409.7K +409.7K (+100.0%) | 0.03% +0.028 pp | 0.01% +0.011 pp | USD27.15 +0.0% | 1 qtrs NEW |
| 71 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 14.7K +12.5K (+573.3%) | 397.8K +356.9K (+871.9%) | 0.03% +0.023 pp | 0.00% +0.000 pp | USD25.23 +7.6% | 5 qtrs — |
| 72 | PROFUND ADVISORS LLC | 14.6K +14.6K (+100.0%) | 395.9K +395.9K (+100.0%) | 0.03% +0.027 pp | 0.01% +0.012 pp | USD27.15 +0.0% | 1 qtrs NEW |
| 73 | GRAHAM CAPITAL MANAGEMENT, L.P. | 13.7K +13.7K (+100.0%) | 372.3K +372.3K (+100.0%) | 0.03% +0.025 pp | 0.01% +0.009 pp | USD27.15 +0.0% | 1 qtrs NEW |
| 74 | LEGAL & GENERAL GROUP PLC | 13.7K +10.8K (+368.8%) | 372.2K +317.2K (+576.7%) | 0.03% +0.020 pp | 0.00% +0.000 pp | USD24.34 +11.5% | 5 qtrs — |
| 75 | CITADEL ADVISORS LLC | 13.4K +13.4K (+100.0%) | 364.4K +364.4K (+100.0%) | 0.02% +0.025 pp | 0.00% +0.000 pp | USD27.15 +0.0% | 1 qtrs NEW |
| 76 | DNB ASSET MANAGEMENT AS | 12.8K +12.8K (+100.0%) | 347.3K +347.3K (+100.0%) | 0.02% +0.024 pp | 0.00% +0.001 pp | USD27.15 +0.0% | 1 qtrs NEW |
| 77 | VIRTU FINANCIAL LLC | 12.2K +12.2K (+100.0%) | 332.0K +332.0K (+100.0%) | 0.02% +0.023 pp | 0.01% +0.013 pp | USD27.15 +0.0% | 1 qtrs NEW |
| 78 | VERITION FUND MANAGEMENT LLC | 12.0K -35.0K (-74.4%) | 326.3K -557.7K (-63.1%) | 0.02% -0.065 pp | 0.00% -0.002 pp | USD13.23 +105.2% | 5 qtrs — |
| 79 | MARINER, LLC | 11.8K +897.0 (+8.2%) | 321.2K +115.5K (+56.2%) | 0.02% +0.002 pp | 0.00% +0.000 pp | USD19.44 +39.7% | 2 qtrs — |
| 80 | CREATIVE PLANNING | 11.7K -2.5K (-17.6%) | 319.0K +50.6K (+18.9%) | 0.02% -0.005 pp | 0.00% +0.000 pp | USD11.11 +144.4% | 3 qtrs — |
| 81 | NEW YORK STATE COMMON RETIREMENT FUND | 11.7K +5.4K (+85.7%) | 317.7K +199.2K (+168.1%) | 0.02% +0.010 pp | 0.00% +0.000 pp | USD17.56 +54.6% | 4 qtrs — |
| 82 | TWO SIGMA INVESTMENTS, LP | 10.5K +— (+0.0%) | 285.1K +87.6K (+44.3%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD18.81 +44.3% | 4 qtrs — |
| 83 | INTECH INVESTMENT MANAGEMENT LLC | 10.4K +— (+0.0%) | 282.3K +86.7K (+44.3%) | 0.02% 0.000 pp | 0.00% +0.001 pp | USD7.49 +262.5% | 4 qtrs — |
| 84 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 10.1K -1.9K (-16.1%) | 275.5K +48.0K (+21.1%) | 0.02% -0.004 pp | 0.00% +0.000 pp | USD10.98 +147.3% | 3 qtrs — |
| 85 | VIRTUS INVESTMENT ADVISERS, INC. | 9.8K -42.0 (-0.4%) | 266.1K +81.0K (+43.7%) | 0.02% 0.000 pp | 0.07% +0.019 pp | USD12.34 +120.0% | 3 qtrs — |
| 86 | STRS OHIO | 9.8K +9.8K (+100.0%) | 266.1K +266.1K (+100.0%) | 0.02% +0.018 pp | 0.00% +0.001 pp | USD27.15 +0.0% | 5 qtrs — |
| 87 | POINT72 ASSET MANAGEMENT, L.P. | 9.7K +9.7K (+100.0%) | 263.4K +263.4K (+100.0%) | 0.02% +0.018 pp | 0.00% +0.000 pp | USD27.15 +0.0% | 1 qtrs NEW |
| 88 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 9.5K +9.0 (+0.1%) | 256.7K +79.0K (+44.5%) | 0.02% +0.000 pp | 0.00% +0.001 pp | USD10.61 +155.9% | 4 qtrs — |
| 89 | PERSISTENT ASSET PARTNERS LTD | 8.9K +8.9K (+100.0%) | 241.8K +241.8K (+100.0%) | 0.02% +0.017 pp | 0.11% +0.109 pp | USD27.15 +0.0% | 1 qtrs NEW |
| 90 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 8.8K +8.8K (+100.0%) | 239.1K +239.1K (+100.0%) | 0.02% +0.016 pp | 0.02% +0.018 pp | USD27.15 +0.0% | 1 qtrs NEW |
| 91 | PROSHARE ADVISORS LLC | 8.4K +8.4K (+100.0%) | 226.8K +226.8K (+100.0%) | 0.02% +0.016 pp | 0.00% +0.000 pp | USD27.15 +0.0% | 1 qtrs NEW |
| 92 | SEI INVESTMENTS CO | 8.1K +8.1K (+100.0%) | 219.6K +219.6K (+100.0%) | 0.02% +0.015 pp | 0.00% +0.000 pp | USD27.15 +0.0% | 1 qtrs NEW |
| 93 | CITIGROUP INC | 6.9K -35.1K (-83.5%) | 188.7K -602.1K (-76.1%) | 0.01% -0.065 pp | 0.00% 0.000 pp | USD18.15 +49.6% | 5 qtrs — |
| 94 | SG AMERICAS SECURITIES, LLC | 5.5K +5.5K (+100.0%) | 150.0K +150.0K (+100.0%) | 0.01% +0.010 pp | 0.00% +0.000 pp | USD27.15 +0.0% | 1 qtrs NEW |
| 95 | BNP PARIBAS ARBITRAGE, SNC | 5.0K -1.6K (-23.8%) | 135.1K +12.3K (+10.0%) | 0.01% -0.003 pp | 0.00% +0.000 pp | USD15.88 +71.0% | 5 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 79 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Virtus Biotech Clinical Trials ETF BBC | 0.76% | 437.3K | 0.65% |
| 2 | Simplify Propel Opportunities ETF SURI | 0.60% | 467.7K | 2.82% |
| 3 | Fidelity Disruptive Medicine ETF FMED | 0.40% | 184.3K | 0.50% |
| 4 | ALPS Medical Breakthroughs ETF SBIO | 0.21% | 447.4K | 0.50% |
| 5 | Vanguard U.S. Momentum Factor ETF VFMO | 0.17% | 2.81M | 0.13% |
| 6 | Fidelity Fundamental Small-Mid Cap ETF FFSM | 0.06% | 849.9K | 0.43% |
| 7 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.03% | 22.8K | 0.35% |
| 8 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.03% | 340.1K | 0.35% |
| 9 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.03% | 130.4K | 0.40% |
| 10 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.03% | 21.0K | 0.19% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
2.00
Bullish
Ratio by volume
3.00
Bullish
Buys
10
Sells
5
Shares acquired
718.0K
Shares disposed
5.0K
Cash buys
—
Cash sales
5.00
Net activity
+712,987
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-16 | Sutherland Everett Rand | Director / Officer | S-Sale | D | Common Stock | 2,093 | 9.29 | 19.4K | 72,907 | D | ↗ |
| 2026-03-16 | Houghton Adam | Officer | S-Sale | D | Common Stock | 699 | 9.29 | 6.5K | 24,301 | D | ↗ |
| 2026-03-16 | GRAY MICHAEL | Officer | S-Sale | D | Common Stock | 852 | 9.29 | 7.9K | 29,648 | D | ↗ |
| 2026-03-16 | Deykin Aaron | Officer | S-Sale | D | Common Stock | 894 | 9.29 | 8.3K | 32,687 | D | ↗ |
| 2026-03-16 | Ambrose Allison | Officer | S-Sale | D | Common Stock | 475 | 9.29 | 4.4K | 16,525 | D | ↗ |
| 2026-01-02 | Sutherland Everett Rand | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 225,000 | 27.07 | 6.09M | 225,000 | D | ↗ |
| 2026-01-02 | Houghton Adam | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 27.07 | 2.03M | 75,000 | D | ↗ |
| 2026-01-02 | GRAY MICHAEL | Officer | A-Award | A | Stock Option (Right to Buy) | 91,500 | 27.07 | 2.48M | 91,500 | D | ↗ |
| 2026-01-02 | Deykin Aaron | Officer | A-Award | A | Stock Option (Right to Buy) | 96,000 | 27.07 | 2.60M | 96,000 | D | ↗ |
| 2026-01-02 | Ambrose Allison | Officer | A-Award | A | Stock Option (Right to Buy) | 51,000 | 27.07 | 1.38M | 51,000 | D | ↗ |
| 2025-06-10 | Ruddy Marcella K. | Director | A-Award | A | Stock Option (Right to Buy) | 17,096 | 11.59 | 198.1K | 17,096 | D | ↗ |
| 2025-06-10 | Renaud Ronald C JR | Director | A-Award | A | Stock Option (Right to Buy) | 17,096 | 11.59 | 198.1K | 17,096 | D | ↗ |
| 2025-06-10 | Ratcliffe Liam | Director | A-Award | A | Stock Option (Right to Buy) | 17,096 | 11.59 | 198.1K | 17,096 | D | ↗ |
| 2025-06-10 | Fleming Harold Edward | Director | A-Award | A | Stock Option (Right to Buy) | 17,096 | 11.59 | 198.1K | 17,096 | D | ↗ |
| 2025-06-10 | Chimovits Erez | Director | A-Award | A | Stock Option (Right to Buy) | 17,096 | 11.59 | 198.1K | 17,096 | D | ↗ |
| 2025-06-10 | Beckman Daniella | Director | A-Award | A | Stock Option (Right to Buy) | 17,096 | 11.59 | 198.1K | 17,096 | D | ↗ |
Executive team
Top executives
EBIT / Employee
-27.6K
Shares Outstanding
54.42M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | E. Rand Sutherland, M.D. Chief Executive Officer | 650.0K | — | — | 3.30M | 341.3K | 10.5K | 4.30M | 76.71% | ↗ |
| 2 | 2025 | Michael Paul Gray, M.B.A. Chief Financial Officer and Chief Operating Officer | 490.0K | — | — | 1.29M | 205.8K | 10.5K | 1.99M | 64.57% | ↗ |
| 3 | 2025 | Aaron Deykin, M.D. Chief Medical Officer and Head of Research and Development | 515.0K | — | — | 1.09M | 216.3K | 10.5K | 1.83M | 59.48% | ↗ |
| 4 | 2024 | E. Rand Sutherland, M.D. Chief Executive Officer | 408.0K | — | — | 8.38M | 315.0K | 10.4K | 9.11M | 91.95% | ↗ |
| 5 | 2024 | Michael Paul Gray, M.B.A. Chief Financial Officer and Chief Operating Officer | 352.7K | — | — | 2.40M | 184.0K | — | 2.94M | 81.74% | ↗ |
| 6 | 2024 | Allison Ambrose, J.D. Sr. Vice President, General Counsel | 17.3K | 42.5K | — | 1.47M | — | — | 1.53M | 96.10% | ↗ |
| 7 | 2024 | Samantha Truex Former Chief Executive Officer | 113.2K | — | — | 120.4K | — | 638.9K | 872.5K | 13.80% | ↗ |
| 8 | 2023 | Samantha Truex Former Chief Executive Officer | 475.0K | — | — | 943.2K | 235.1K | 9.9K | 1.66M | 56.71% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| E. Rand Sutherland | Chief Executive Officer & Director | 1M | — |
| Aaron Deykin | Chief Medical Officer and Head of Research & Development | 741.8K | male |
| Michael Paul Gray | Chief Financial Officer & Chief Operating Officer | 706.3K | male |
| Allison Ambrose | Senior Vice President, General Counsel & Secretary | 59.8K | female |
| Meggan Buckwell | Director of Corporate Communications & Investor Relations | — | — |
| Mersedeh Miraliakbari | Senior Vice President of Regulatory Affairs & Quality | — | female |
| Stacy Price | Chief Technology Officer | — | female |
| Adam Houghton | Chief Business Officer | — | male |
| Fang Xie | Vice President & Head of Biometrics | — | female |
| Lisa Fiering | Senior Vice President of People & Culture | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for UPB
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
